Eradivir
Business Services · Indiana, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
West Lafayette, Indiana, United StatesWebsite
www.eradivir.comRevenue
$6 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Eradivir
Eradivir's goal is to focus on the power of the immune system to treat disease. Eradivir's small molecule based Bispecific Antigenic immuno-Therapy (BAiT) technology tethers a patients immune cells specifically to a diseased cell facilitating its rapid and selective destruction. With a toolkit of these small-molecule immunotherapies, Eradivir will be able to develop pharmaceuticals to treat and cure multiple diseases, including viral infections and cancer.Explore more
Eradivir Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Eradivir your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Eradivir has new funding data
Earning: See what the market has to say on Eradivir recently announced quarterly report
Website visits: Recent activity has been detected on your website
Click to see if Eradivir had a recent Job posting/layoffs
Check out if Eradivir is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Eradivir launches new products
Check if Eradivir has recently received funding, and reach out quickly before it becomes old news!
Eradivir, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Eradivir
Recommended Actions
Reach out to Masked Content who joined Eradivir as Masked Content
Find more new buyers
Company Profile Activity
Activity Insights
Eradivir is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Eradivir is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Eradivir.
Eradivir financials insights
Gather financial insights about Eradivir, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2024
Series A
$10.3M
2025
Private Equity
$10M
Eradivir Tech Stack
A closer look at the technologies used by Eradivir
See more technologies
Most Recent Scoops
Funding
Funding
Event
Product Marketing, Events, Learning & Development, Software, Bioengineering, Pharmaceuticals, Public Health, Field /Outside Sales, Field Marketing, Healthcare Technology, Patient Experience
Funding
Funding
Funding
Eradivir News & Media
Eradivir To Present At 2025 Biotechnology Innovation Organization (BIO) International Convention
WEST LAFAYETTE, Ind.--(BUSINESS WIRE)-- #BIO2025--Eradivir Inc., a clinical-stage biotechnology company that harnesses the power of the immune system to target and treat disease, today announced it will present at the Biotechnology Innovation Organization (BIO) International Convention taking place in Boston, Mass., on Tuesday, June 17, 2025, beginning at 4 p.m. in room 153A. Eradivir’s lead antiviral therapeutic EV25 is currently in a Phase 2 challenge study for the treatment of influenza. PrecEradivir announces Phase 2 human challenge study of EV25 in healthy adults infected with influenza
Challenge study follows Phase 1 study that found EV25 is well tolerated in humans Challenge study follows Phase 1 study that found EV25 is well tolerated in humansEradivir’s EV25 therapeutic proven to reduce advanced-stage influenza viral loads faster, more thoroughly in preclinical studies than current therapies
Research has been published in Proceedings of the National Academy of Sciences Research has been published in Proceedings of the National Academy of Sciences
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Eradivir
Sign Up For FreeTo access detailed company insights
Eradivir's goal is to focus on the power of the immune system to treat disease. Eradivir's small molecule based Bispecific Antigenic immuno-Therapy (BAiT) technology tethers a patients immune cells specifically to a diseased cell facilitating its rapid and selective destruction. With a toolkit of these small-molecule immunotherapies, Eradivir will... Read More
